Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection

Drug Discovery Today

Volumn 15, Issue 5-6, 2010, Pages 186-197

  Tan, Jian J ^a   Cong, Xiao J ^a   Hu, Li M ^a   Wang, Cun X ^a   Jia, Lee ^b   Liang, Xing Jie ^b  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; AMINOGLYCOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DIDANOSINE; EFAVIRENZ; EMIVIRINE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; MSC 204; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; PLERIXAFOR; PROTEINASE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER AIDED DESIGN; CONFORMATIONAL TRANSITION; DRUG APPROVAL; DRUG DESIGN; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DOCKING; MOLECULAR MECHANICS; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIMULATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; DISEASE MANAGEMENT; DRUG DISCOVERY; HIV INFECTIONS; HUMANS;

EID: 77649232123     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.01.004     Document Type: Review

References (125)

1. Girard M.P., et al. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
2. Barbaro G., et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11 (2005) 1805-1843
3. Louie M., and Markowitz M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res. 55 (2002) 15-25
4. Greene W.C. The brightening future of HIV therapeutics. Nat. Immunol. 5 (2004) 867-871
5. Hazuda D., et al. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 377-394
6. DiMasi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
7. Kwong P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
8. Speck R.F., et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J. Virol. 71 (1997) 7136-7139
9. Chan D.C., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
10. Kong R., et al. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Biochim. Biophys. Acta 1764 (2006) 766-772
11. Lifson J.D., and Engleman E.G. Role of Cd4 in normal immunity and HIV infection. Immunol. Rev. 109 (1989) 93-117
12. Wang J.H., et al. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10799-10804
13. Myszka D.G., et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9026-9031
14. Neffe A.T., and Meyer B. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Angew. Chem. Int. Ed. Engl. 43 (2004) 2937-2940
15. Neffe A.T., et al. Synthesis and optimization of peptidomimetics as HIV entry inhibitors against the receptor protein CD4 using STD NMR and ligand docking. Org. Biomol. Chem. 4 (2006) 3259-3267
16. Goldgur Y., et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13040-13043
17. Neffe A.T., et al. Rational optimization of the binding affinity of CD4 targeting peptidomimetics with potential anti HIV activity. J. Med. Chem. 50 (2007) 3482-3488
18. Schlyer S., and Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today 11 (2006) 481-493
19. Roy K., and Leonard J.T. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists. J. Chem. Inf. Model. 45 (2005) 1352-1368
20. Aher Y.D., et al. 3D-QSAR studies of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists. J. Mol. Model. 13 (2007) 519-529
21. Dessalew N. QSAR study on piperidinecarboxamides as antiretroviral agents: an insight into the structural basis for HIV coreceptor antagonist activity. QSAR Comb. Sci. 27 (2008) 901-912
22. Afantitis A., et al. Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques. J. Comput. Aided Mol. Des. 20 (2006) 83-95
23. Leonard J.T., and Roy K. Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. Bioorg. Med. Chem. Lett. 16 (2006) 4467-4474
24. Zhuo Y., et al. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors. Eur. J. Med. Chem. 43 (2008) 2724-2734
25. Finke P.E., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11 (2001) 2475-2479
26. Xu Y., et al. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor. Bioorg. Med. Chem. 12 (2004) 6193-6208
27. Kellenberger E., et al. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J. Med. Chem. 50 (2007) 1294-1303
28. Este J.A., et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. 55 (1999) 67-73
29. Pettersson S., et al. Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors. ChemMedChem 3 (2008) 1549-1557
30. Pascual R., et al. Design and analysis of a combinatorial library of HEPT analogues: comparison of selection methodologies and inspection of the actually covered chemical space. J. Chem. Inf. Comput. Sci. 43 (2003) 199-207
31. Lapidot A., and Borkow G. Multi-targeting the entrance door to block HIV-1 by aminoglycoside-arginine conjugates (AACs). Biopolymers 80 (2005) 536
32. Hegde R., et al. Structure-function relationship of novel X4 HIV-1 entry inhibitors - l- and d-arginine peptide-aminoglycoside conjugates. FEBS J. 274 (2007) 6523-6536
33. Berchanski A., and Lapidot A. Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure. Biochim. Biophys. Acta 1768 (2007) 2107-2119
34. Katchalski-Katzir E., et al. Molecular-surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2195-2199
35. Jorissen R.N., et al. Additivity in the analysis and design of HIV protease inhibitors. J. Med. Chem. 52 (2009) 737-754
36. Berchanski A., and Lapidot A. Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. J. Mol. Model. 15 (2009) 281-294
37. Root M.J., et al. Protein design of an HIV-1 entry inhibitor. Science 291 (2001) 884-888
38. Tan J.J., et al. Investigating interactions between HIV-1 gp41 and inhibitors by molecular dynamics simulation and MM-PBSA/GBSA calculations. J. Mol. Struct. THEOCHEM 766 (2006) 77-82
39. Tan J.J., et al. Studies on binding free energies and the binding mode by docking and MM-PBSA in gp41-ligand complex. Mol. Simul. 31 (2005) 1051-1056
40. Tan J.J., et al. Gp41 hydrophobic pocket entry inhibitor linear interaction energy MD simulation. J. Mol. Struct. THEOCHEM 682 (2004) 9-15
41. Green D.F., and Tidor B. Design of improved protein inhibitors of HIV-1 cell entry: optimization of electrostatic interactions at the binding interface. Proteins: Struct. Func. Bioinf. 60 (2005) 644-657
42. Jiang S.B., et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Ch. 48 (2004) 4349-4359
43. Liu K., et al. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem. 51 (2008) 7843-7854
44. Goff S.P. Retroviral reverse-transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 3 (1990) 817-831
45. Da Silva C.H.T.P., et al. Molecular dynamics, docking, density functional, and admet studies of HIV-1 reverse transcriptase inhibitors. J. Theor. Comput. Chem. 5 (2006) 579-586
46. Ren J., et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 275 (2000) 14316-14320
47. Barreca M.L., et al. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem. 48 (2005) 3433-3437
48. Wittayanarakul K., et al. Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. Biophys. J. 88 (2005) 867-879
49. Menendez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23 (2002) 381-388
50. Saparpakorn P., et al. Design of nevirapine derivatives insensitive to the K103N and Y181CHIV-1 reverse transcriptase mutants. SAR QSAR Environ. Res. 17 (2006) 183-194
51. Zhang Z., et al. Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues. J. Comput. Aided Mol. Des. 20 (2006) 281-293
52. Pauwels R., et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 (1990) 470-474
53. Sapre N.S., et al. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1NNRT inhibitors. J. Comput. Aided Mol. Des. 22 (2008) 69-80
54. Thomsen R., and Christensen M.H. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 49 (2006) 3315-3321
55. Sapre N.S., et al. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors. J. Mol. Model. 14 (2008) 1009-1021
56. Restle T., et al. Rnase-H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 300 (1992) 97-100
57. Mulky A., et al. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J. Mol. Biol. 349 (2005) 673-684
58. Grohmann D., et al. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. ChemBioChem 9 (2008) 916-922
59. Ren J., et al. High-resolution structures of HIV-1 RT from 4 RT-inhibitor complexes. Nat. Struct. Biol. 2 (1995) 293-302
60. Kale L., et al. NAMD2: greater scalability for parallel molecular dynamics. J. Comput. Phys. 151 (1999) 283-312
61. MacKerell Jr. A.D., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102 (1998) 3586-3616
62. Boobbyer D.N.A., et al. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 32 (1989) 1083-1094
63. Esposito D., and Craigie R. HIV integrase structure and function. Adv. Virus Res. 52 (1999) 319-333
64. Fenollar-Ferrer C., et al. HIV-1 integrase-DNA interactions investigated by molecular modelling. Comput. Math. Methods Med. 9 (2008) 231-243
65. Goldgur Y., et al. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9150-9154
66. Chen J.C.H., et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8233-8238
67. Wang J.Y., et al. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20 (2001) 7333-7343
68. Rosemond M.J.C., et al. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem. Biol. Interact. 147 (2004) 129-139
69. Johnson A.A., et al. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr. Top. Med. Chem. 4 (2004) 1059-1077
70. Markowitz M., et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43 (2006) 509-515
71. DeJesus E., et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43 (2006) 1-5
72. Deprez E., et al. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65 (2004) 85-98
73. Hong H., et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 40 (1997) 930-936
74. Barreca M.L., et al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48 (2005) 7084-7088
75. Li H., et al. HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. Pharmacophore Perception, Development, and Use in Drug Design (2000), International University
76. Dayam R., et al. beta-Diketo acid pharmacophore hypotesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem. 48 (2005) 111-120
77. Dayam R., et al. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J. Med. Chem. 51 (2008) 1136-1144
78. Mugnaini C., et al. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg. Med. Chem. Lett. 17 (2007) 5370-5373
79. Nicklaus M.C., et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 40 (1997) 920-929
80. Deng J., et al. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorg. Med. Chem. 15 (2007) 4985-5002
81. Zsoldos Z., et al. eHITS: an innovative approach to the docking and scoring function problems. Curr. Protein Pept. Sci. 7 (2006) 421-435
82. Espeseth A.S., et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11244-11249
83. Zhu H.M., et al. Docking dinucleotides to HIV-1 integrase carboxyl-terminal domain to find possible DNA binding sites. Bioorg. Med. Chem. Lett. 15 (2005) 475-477
84. Wang L.D., et al. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun. 337 (2005) 313-319
85. Chen X., et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380 (2008) 504-519
86. Jin H., et al. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 3989-3992
87. Ferro S., et al. Docking studies on a new human immuodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. J. Med. Chem. 52 (2009) 569-573
88. Maroun R.G., et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40 (2001) 13840-13848
89. Lapatto R., et al. X-ray-analysis of HIV-1 proteinase at 2.7 a resolution confirms structural homology among retroviral enzymes. Nature 342 (1989) 299-302
90. Levy Y., and Caflisch A. Flexibility of monomeric and dimeric HIV-1 protease. J. Phys. Chem. B 107 (2003) 3068-3079
91. Boggetto N., and Reboud-Ravaux M. Dimerization inhibitors of HIV-1 protease. Biol. Chem. 383 (2002) 1321-1324
92. Free S.M., and Wilson J.W. A mathematical contribution to structure-activity studies. J. Med. Chem. 7 (1964) 395-399
93. Frecer V., et al. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1. Bioorg. Med. Chem. 13 (2005) 5492-5501
94. Jorgensen W.L., and Duffy E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 54 (2002) 355-366
95. Frecer V., et al. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties. J. Mol. Graph. Model. 27 (2008) 376-387
96. Durdagi S., et al. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations. Bioorg. Med. Chem. 16 (2008) 9957-9974
97. Rutenber E., et al. Structure of a nonpeptide inhibitor complexed with HIV-1 protease - developing a cycle of structure-based drug design. J. Biol. Chem. 268 (1993) 15343-15346
98. Van der Spoel D., et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26 (2005) 1701-1718
99. Davis B., et al. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J. Mol. Biol. 336 (2004) 343-356
100. Liu Y., et al. Structure-activity relationships of 1′-acetoxychavicol acetate homologues as new nuclear export signal inhibitors. Pharmazie 62 (2007) 659-662
101. Emert-Sedlak L., et al. Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem. Biol. 4 (2009) 939-947
102. Shafer R.W., et al. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J. Virol. 73 (1999) 6197-6202
103. Wartha F., et al. Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance. J. Chem. Theory Comput. 1 (2005) 315-324
104. Ode H., et al. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J. Mol. Biol. 370 (2007) 598-607
105. Aruksakunwong O., et al. Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations. J. Mol. Graph. Model. 25 (2006) 324-332
106. Saen-oon S., et al. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations. J. Mol. Graph. Model. 26 (2007) 720-727
107. Friesner R.A., and Beachy M.D. Quantum mechanical calculations on biological systems. Curr. Opin. Struct. Biol. 8 (1998) 257-262
108. Morokuma K. New challenges in quantum chemistry: quests for accurate calculations for large molecular systems. Philos. Transact. A: Math. Phys. Eng. Sci. 360 (2002) 1149-1164
109. Das K., et al. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88 (2005) 209-231
110. Bacheler L., et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75 (2001) 4999-5008
111. Juan A.A.S. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. Bioorg. Med. Chem. Lett. 18 (2008) 1181-1194
112. Amaro R.E., et al. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des. 22 (2008) 693-705
113. Kollman P. Free-energy calculations: applications to chemical and biochemical phenomena. Chem. Rev. 93 (1993) 2395-2417
114. Aqvist J., et al. Ligand binding affinities from MD simulations. Acc. Chem. Res. 35 (2002) 358-365
115. Kollman P.A., et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33 (2000) 889-897
116. Okimoto N., et al. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLOS Comput. Biol. 5 (2009) e1000528
117. Zhou Z.G., and Madura J.D. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS. Proteins: Struct. Func. Bioinf. 57 (2004) 493-503
118. Tickle I., et al. High-throughput protein crystallography and drug discovery. Chem. Soc. Rev. 33 (2004) 558-565
119. Guvench O., and MacKerell A.D. Computational fragment-based binding site identification by ligand competitive saturation. PLOS Comput. Biol. 5 (2009) e1000435
120. Clark M., et al. fragment-based computation of binding free energies by systematic sampling. J. Chem. Inf. Model. 49 (2009) 1901-1913
121. Deng Y., and Roux B. Computations of standard binding free energies with molecular dynamics simulations. J. Phys. Chem. B 113 (2009) 2234-2246
122. Fukunishi Y., et al. The filling potential method: a method for estimating the free energy surface for protein-ligand docking. J. Phys. Chem. B 107 (2003) 13201-13210
123. Kumar S., et al. The weighted histogram analysis method for free-energy calculations on biomolecules. 1. The method. J. Comput. Chem. 13 (1992) 1011-1021
124. Fukunishi Y., et al. Protein-ligand binding free energy calculation by the smooth reaction path generation (SRPG) method. J. Chem. Inf. Model. 49 (2009) 1944-1951
125. Almlöf M., et al. Improving the accuracy of the linear interaction energy method for solvation free energies. J. Chem. Theory Comput. 3 (2007) 2162-2175